Company profile: Chromatin
1.1 - Company Overview
Company description
- Provider of plant breeding and genomics technologies for agricultural, energy, chemical, nutritional and pharmaceutical sectors. Develops sorghum for agriculture and renewable energy, and advances maize and wheat via high-yielding, disease- and climate-resilient traits. Services include genomic selection, high-throughput phenotyping, multi-trait analysis, environics for genotype prediction, and integrated genomics-phenomics modeling.
Products and services
- Genomic Selection: Chromatin implements data-driven genomic selection to improve breeding values, reduce breeding cycle time, and enhance selection accuracy in maize and wheat improvement pipelines
- Maize Research: Chromatin architects field-validated superior maize hybrids to enhance food security and livelihoods, focusing on stress tolerance, nutritional quality, and disease resistance
- Wheat Research: Chromatin engineers collaboratively-bred high-yielding, disease-resistant, climate-resilient wheat varieties through partnerships with global research and breeding institutes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Chromatin
Singleron
HQ: China
Website
- Description: Provider of clinical diagnosis, health management, and drug development products and services, dedicated to applying single cell analysis techniques. Holds a worldwide exclusive IP license from Yale University for a uniquely designed microfluidic single cell processing device.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Singleron company profile →
RootPath
HQ: United States
Website
- Description: Provider of a personalized T cell therapy platform and gene synthesis solutions, including PathFinder DNA Assembly™ for accurate long-gene construction, Molecular Toothpick™ for error screening and recovery, PathFinder Custom Gene Library™ with sequence-verified plasmids, genes and fragments at scale (300 bp–10 kb), mutagenesis and variant libraries, and recombinant antibodies with CHO-cell expression and characterization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RootPath company profile →
BC Platforms
HQ: Switzerland
Website
- Description: Provider of data and technology platforms for life sciences and healthcare, enabling access, management, and analysis of clinical, genomic, and omics data. Offers a federated Global Data Network, secure data environments, analytics and AI/federated analytics, and scientific services supporting pharmaceutical research, clinical trials, and real-world data studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BC Platforms company profile →
SeQure Dx
HQ: United States
Website
- Description: Provider of safety data and diagnostic platforms for on- and off-target CRISPR gene editing therapies. Offers NoteSeQ (ONE-seq) for profiling off-target sites, ScopeSeQ for validating candidate edits via next-generation sequencing, risk assessment across the development lifecycle, discovery/IND support, clinical trial patient risk management, and post-approval diagnostic management with patient and physician education.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SeQure Dx company profile →
Signal Genetics
HQ: United States
Website
- Description: Provider of innovative molecular diagnostic services that help physicians make better-informed decisions in the care of patients with cancer; a commercial-stage molecular diagnostics company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Signal Genetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Chromatin
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Chromatin
2.2 - Growth funds investing in similar companies to Chromatin
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Chromatin
4.2 - Public trading comparable groups for Chromatin
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →